Composition : Entavir-0.5: Entecavir USP 0.5 mg Tablet.
Entavir-1: Entecavir USP 1 mg Tablet.
Indication: This tablet is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases or histologically active disease.
Dosage and administration : The recommended dose of Entecavir for chronic hepatitis B virus infection in nucleoside-treatment-naive adults and adolescents 16 years of age and older is 0.5mg once daily. The recommended dose of Entecavir in adults and adolescents (>16years of age) with a history of hepatitis B viremia while receiving lamivudine is 1mg once daily. Entecavir should be administered on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal). Or, as directed by the registered physician.
Use in pregnancy and lactation : Entecavir should be used during pregnancy only if clearly needed and after careful consideration of the risks and benefits. It is not known whether this drug is excreted in human milk. Mothers should be instructed not to breast feed if they are taking Entecavir.
Packing: Entavir-0.5: 1x14’s tablets in blister pack.
Entavir-1: 1x14’s tablets in blister pack.
© Copyright Drug International Ltd. 2023 Designed and Developed by ATI Limited.